title: Mixed-effects beta regression for modeling continuous bounded outcome scores using NONMEM when data are not on the boundaries.
abstract: Beta regression models have been recommended for continuous bounded outcome scores that are often collected in clinical studies. Implementing beta regression in NONMEM presents difficulties since it does not provide gamma functions required by the beta distribution density function. The objective of the study was to implement mixed-effects beta regression models in NONMEM using Nemes' approximation to the gamma function and to evaluate the performance of the NONMEM implementation of mixed-effects beta regression in comparison to the commonly used SAS approach. Monte Carlo simulations were conducted to simulate continuous outcomes within an interval of (0, 70) based on a beta regression model in the context of Alzheimer's disease. Six samples per subject over a 3 years period were simulated at 0, 0.5, 1, 1.5, 2, and 3 years. One thousand trials were simulated and each trial had 250 subjects. The simulation-reestimation exercise indicated that the NONMEM implementation using Laplace and Nemes' approximations provided only slightly higher bias and relative RMSE (RRMSE) compared to the commonly used SAS approach with adaptive Gaussian quadrature and built-in gamma functions, i.e., the difference in bias and RRMSE for fixed-effect parameters, random effects on intercept, and the precision parameter were <1-3 %, while the difference in the random effects on the slope was <3-7 % under the studied simulation conditions. The mixed-effect beta regression model described the disease progression for the cognitive component of the Alzheimer's disease assessment scale from the Alzheimer's Disease Neuroimaging Initiative study. In conclusion, with Nemes' approximation of the gamma function, NONMEM provided comparable estimates to those from SAS for both fixed and random-effect parameters. In addition, the NONMEM run time for the mixed beta regression models appeared to be much shorter compared to SAS, i.e., 1-2 versus 20-40 s for the model and data used in the manuscript.
authors: Model-Based Drug Development, Janssen Research & Development, 920 Route 202, Raritan, NJ, USA. sxu26@its.jnj.com
authors: Xu Steven
authors: XS
authors: Xu
authors: Mahesh N
authors: MN
authors: Samtani
authors: Adrian
authors: A
authors: Dunne
authors: Partha
authors: P
authors: Nandy
authors: An
authors: A
authors: Vermeulen
authors: Filip
authors: F
authors: De Ridder
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000473:pathology; D003198:Computer Simulation; D018450:Disease Progression; D006801:Humans; D008875:Middle Aged; D015233:Models, Statistical; D009010:Monte Carlo Method; D016011:Normal Distribution; D012044:Regression Analysis
references: Psychol Methods. 2006 Mar;11(1):54-71
references: 16594767
references: J Nutr Health Aging. 2007 Jul-Aug;11(4):348-52
references: 17653497
references: J Clin Pharmacol. 2012 May;52(5):629-44
references: 21659625
references: Alzheimers Dement. 2011 Mar;7(2):151-60
references: 20810324
references: J Pharmacokinet Pharmacodyn. 2011 Aug;38(4):497-517
references: 21688068
references: Alzheimers Dement. 2010 Jan;6(1):39-53
references: 19592311
references: Stat Med. 2008 Dec 30;27(30):6612-33
references: 18816501
references: J Pharmacokinet Pharmacodyn. 2012 Dec;39(6):601-18
references: 22990808
references: J Pharmacokinet Pharmacodyn. 2012 Oct;39(5):479-98
references: 22821139
references: Stat Med. 2011 Apr 30;30(9):935-49
references: 21472758
references: Am J Occup Ther. 1999 Sep-Oct;53(5):471-81
references: 10500855